Pertuzumab combination therapy of HER2-positive metastic breast cancer

• Research type

  Research Study

• Full title

  A multicentre randomised phase II study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA)

• IRAS ID

  48200

• Contact name

  Andrew Wardley

• Contact email

  Andrew.Wardley@christie-tr.nwest.nhs.uk

• Sponsor organisation

  F. Hoffmann-La Roche Ltd.

• Eudract number

  2008-006801-17

• ISRCTN Number

  not available

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Exceeds word count do not publish

• REC name

  Scotland A REC

• REC reference

  10/MRE00/21

• Date of REC Opinion

  13 Apr 2010

• REC opinion

  Further Information Favourable Opinion